Legato Capital Management LLC Makes New Investment in Profound Medical $PROF

Legato Capital Management LLC acquired a new position in shares of Profound Medical (NASDAQ:PROF) in the 4th quarter, HoldingsChannel reports. The firm acquired 99,668 shares of the company’s stock, valued at approximately $784,000.

Other large investors also recently bought and sold shares of the company. First Eagle Investment Management LLC boosted its holdings in shares of Profound Medical by 138.8% during the 3rd quarter. First Eagle Investment Management LLC now owns 291,391 shares of the company’s stock worth $1,451,000 after purchasing an additional 169,352 shares during the last quarter. Perkins Capital Management Inc. acquired a new position in shares of Profound Medical during the 4th quarter worth approximately $899,000. Royce & Associates LP boosted its holdings in shares of Profound Medical by 12.4% during the 3rd quarter. Royce & Associates LP now owns 859,906 shares of the company’s stock worth $4,202,000 after purchasing an additional 95,000 shares during the last quarter. CM Management LLC acquired a new position in shares of Profound Medical during the 4th quarter worth approximately $630,000. Finally, Ring Mountain Capital LLC boosted its holdings in shares of Profound Medical by 15.0% during the 4th quarter. Ring Mountain Capital LLC now owns 454,080 shares of the company’s stock worth $3,733,000 after purchasing an additional 59,216 shares during the last quarter. 47.86% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Profound Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Profound Medical Price Performance

NASDAQ:PROF opened at $6.83 on Tuesday. The stock’s fifty day moving average is $6.48 and its two-hundred day moving average is $6.85. Profound Medical has a 52 week low of $3.76 and a 52 week high of $8.95. The stock has a market capitalization of $248.20 million, a price-to-earnings ratio of -5.51 and a beta of 0.73.

Profound Medical (NASDAQ:PROF) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.05. The company had revenue of $5.34 million for the quarter, compared to analysts’ expectations of $4.85 million. Profound Medical had a negative return on equity of 78.88% and a negative net margin of 206.76%. On average, sell-side analysts expect that Profound Medical will post -0.86 EPS for the current fiscal year.

Profound Medical Company Profile

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.